PATIENTS: Noone wants to be told they are cancer free, then discover a short while later that the cancer (that was missed) has spread further and is now attacking somewhere else.
DOCTORS: Your patients won't thank you for giving them an inferior test when a better one exists. So, for Louise and co, this is the most natural progression. They have been public about this test that seems to be so much better! Only through research can they access and use this better diagnostic. It's a win win win (patient, doctor, company).
SOCIETY: Most definitely. Delayed treatment costs a lot more due to complications, more extensive therapies, loss of economic activity due to the patient missing work, etc.
CLARITY (the business): If this proves to be the best in class, Clarity's value will sky rocket. Imagine the perfect paring: Diagnose with the best (Cu64), and treat with the best (Cu67). Who would choose to be diagnosed using Cu64 and then get treated with Pluvicto, if the perfect pairing proves to be perfect? Also remember that the company can use the data in its applications for filing with the various authorities.
Costs? The tendency is for the company to provide some or all product free of charge, while the hospital covers staff costs as normal.
CU6 Price at posting:
$6.27 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)